MARIETTA, Ga., Nov. 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at the Canaccord|Genuity Forum in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, and Bill Taylor, President & COO, are scheduled to present on Thursday, November 9, 2017 at 8:00 a.m. eastern time, at the Westin Grand Central Hotel. A webcast of the presentation will be available on the Company's website, www.mimedx.com.
MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
View original content:http://www.prnewswire.com/news-releases/mimedx-to-present-at-the-canaccordgenuity-medical-technology-and-diagnostics-forum-300548670.html
SOURCE MiMedx Group, Inc.
PRESS RELEASE CONTACT: Michael Senken, Phone: (770) 651-9100; Investor Contact: COCKRELL GROUP, Rich Cockrell, 877-889-1972, firstname.lastname@example.org, cockrellgroup.com